

\*\*

\*

---

29			56	:
	$\mu\text{g}$ 800			.27
	12	$\mu\text{g}$ 200	$\mu\text{g}$ 200	
	48		6	
	%95.5	%100		:
	20.2	8.1		%100
			17.8	12.4
	%10			%85.7
				(P < 0.001)
	6	12		:

---

\*  
\*\*

---

## A Comparison of Two Dosing Regimens of Intravaginal Misoprostol for First and Second- Trimesters Pregnancy Termination

\*Bashar AL- Kurdi

\*\*Mohammed Tabbaa

---

### Abstract

**Objective:** To compare the effectiveness of Misoprostol administered intravaginally every 12 versus 6 hours for termination of pregnancy in the first and second trimesters.

**Methods:** Fifty six pregnant patients at 7 – 22 weeks of gestation were randomized to receive 800 µg (first trimester) and 200 µg either every 12 or every 6 hours for 48 hours.

**Results:** The incidence of abortion within 48 hours after initial dose, in the first trimester was 100% in the two groups, in the second trimester the incidences were 95.5 and 100%. The incidences of abortion by a single dose in the first trimester were 85 and 10% in the 12 and 6 hours groups respectively (P <0.001) The mean abortion intervals 8.3 , 20.2 and 12.4 hours in the 12 and 6 hour group respectively. Side effects were similar in both groups.

**Conclusion:** Misoprostol administered vaginally is effective for termination of first and second trimester pregnancies in non scared uterus. Giving the medication at a shorter interval from 12 to 6 hours appeared to have no significant benefit.

---

\* Prof. Dep. Of Obstetrics and Gynecology- Damascus University.

\*\* Ass. Prof. Dep. Of Obstetrics and Gynecology- Damascus University.

:

Misoprostol

.(2) E1

(4.5.7.8)

.(3.10)

(8.4.5)

.(9)

.(3)

---

12 800 :

μg 200

12

. μg 200 . :

27 :

. 6

(7)

4

) 56 :

.(

) .(11.1) % 5

29

Cytotec; Searle, )

.(

(Skkokie


.(7)  
48  
:  
12  
( )  
(8.5.7)  
500 12  
% 5  
) 50  
3  
( 3 100  
(Taiwan.1423.Medical) 300  
(1) .(6)  
(11) 12  
-  
(Casio H L)

:

(1)

(1) M±m

P	N=27	N=29	
> 0.05	27.1	30.3	( )
> 0.05 > 0.05	(% 22.2)6 (% 77.8)21	(% 20.7) 6 (% 79.3)23	:
> 0.05 > 0.05	(% 37)10 (% 63)17	(% 24.1)7 (% 75.9)22	: 12 ≥ 12 <
> 0.05	(% 59.3)16	(% 41)12	



(1)

: (2)  
(2)

P	N=27	N=29	
> 0.05	(% 77.8) 21	(% 82.8)24	) (
> 0.05	0	(% 3.4) 1	
> 0.05	(% 14.8)4	(% 6.9) 2	
> 0.05	0	(% 3.4)1	
> 0.05	(% 3.7)1	0	
> 0.05	(% 3.7)1	(% 3.4)1	
-	27	29	

---

P > )

(2)

(3)

.(0.05

( )




( % 78 , % 83)

(3)

P	P	n=27	n=29	
---	---	------	------	--



-	-	12 < (n=17)	12 ≥ (n=10)	12 < (n=22)	12 ≥ (n=7)	-
> 0.05	< 0.05	0.7±17.8	1.2±12.4	1.2±20.2	1.5±8.13	± m M
> 0.05	> 0.05	(%100)17	(%100)10	(%95.5)21	(%100)7	
> 0.05	> 0.05	(%58.8)10	(%70)7	(%68.2)15	(%100)7	
> 0.05	<0.001	(%11.8)2	(%10)1	(%36.3)8	(%85.7)6	:
> 0.05	< 0.05	(%23.5)4	(%70)7	(%27.3)6	(%14.3)1	
> 0.05	> 0.05	(%17.6)3	(%20)2	(%9.1)2	0	
> 0.05	> 0.05	(%47.1)8	0	(%27.3)6	0	



---

||

86

(3)

%

12

12

%10

8


.(P<0.001)

12

.(0.05 >P)

6

108




(4)

(4)

P	n=27	n=29	
> 0.05	(%14.8)4	(%24.1)7	
> 0.05	(%11.1)3	(%13.8)4	
> 0.05	(%7.4)2	(%6.9)2	
> 0.05	(%14.8)4	(%3.4)1	
> 0.05	0	(%3.4)1	

> 0.05	0	(%3.4)1	
> 0.05	(%3.7)1	0	
> 0.05	0	(%3.4)1	



2.21

8

(P< 0.001)

1.2 .

- 2004 - - -

---

12 .% 38 (%43.5)10

5-3

% 96 (%14.8)4

John K. % 89 .(P < 0.01)

.(4) 1999

% 88 % 100 :

μg 800

6 12 ساعة μg 200

% 41 % 32

John K. % 33 % 100

.(4) 1999 Mitchell D)

((5)1999 John K 1997

13.8 14 18.20 24 μg 800

% 88

27 1997 Mika .

6.9

% 3.2 %

% 13 - 1997 Mitchell D

μg 800

200

12 µg , 48 12 µg 200  
48  
6

- 1- Altman D G. How large a sample ? In: Gore S M, Altman D G, eds. *Statistics in Practice*. London: British Medical Association, 1982: 6-8 .
- 2- Garris R E, Kirkwood C F. Misoprostol: A prostaglandin E-1 analogue *Clin pharm* 1989; 8:627-644.
- 3- Herting R L, Nissen C H. Overview of misoprostol clinical experience. *Dig Dis Sci* 1986; 31 (suppl 2) : 47s-54s.
- 4- John K. Jaain, John Kuo and Danial R. Mishell. Comparison of Two Dosing Regimens of Intravaginal Misoprostol for Second-Trimester Pregnancy Termination. *American Jour. of Obst. And Gyn.* April.1999.Vol.93,No. 4, P. 571-575.
- 5- John K Jain, Karen R. Meckstroth and Daniel R. Mishell Jr. Early pregnancy termination with intravaginal administered sodium chloride solution-moistened misoprostol tables: Historical comparison, *American Jour Of Obst. And Gyn* December 1999.Vol 181 No. 1386-91.
- 6- Jonathan S. Berek, Eli Y. Adashi, Paula A. Hillard / Novak’s *Gynecology* . 12<sup>th</sup>. Edition . 1996. P.268.
- 7- Mika Nuutila, Juhani Toivonen, Olavi Ylikorkla and Erja Halmesminki/ A Comparison Between Two Doses of Intravaginal

Misopostol and Gemp for Induction of Second-Trimester Abortion. American Jour. of Obst. And Gynec. Vol. 90, No. 6, December, 1997, P. 896-900s.

- 8- Mitchell D Creinin, Robert Moyer and Richard Guido. Misoprostol for Medical Evacuation of Early Pregnancy Failure. American Jour of Obst. And Gynec., Vol 89, No. 5, Part 1, May 1997.
- 9- Rabe T, basse H, Thuro H, Kiesel L, Runnebaum B. Wirkung des PG E-1 Methylanalogons misoprostol auf den schw uterus im ersten trimester.
- 10- Rafeay H, Calder L, Wheatly D N, Templeton A. cervical priming with prostaglandin E1 analouges, Misoprostol and gemeprost. Lancet 1994;343: 1207-1209
- 11- Serenko A. F. , Ermakova V .V. / Socisl hygiene and orginizationof health services 1977, P 672.

---

.2002 /8 /3 :

.2003 /3 /30: